Could BIOTRON LTD (OTCMKTS:BITRF) Change Direction After More Shorts?

January 13, 2018 - By Kurt Siggers

The stock of BIOTRON LTD (OTCMKTS:BITRF) registered an increase of 66.67% in short interest. BITRF’s total short interest was 10,000 shares in January as published by FINRA. Its up 66.67% from 6,000 shares, reported previously. With 15,800 shares average volume, it will take short sellers 1 days to cover their BITRF’s short positions.

It closed at $0.027 lastly. It is down 0.00% since January 13, 2017 and is . It has underperformed by 16.70% the S&P500.

Biotron Limited, a biotechnology company, develops and commercializes novel small molecule antiviral therapeutics to treat various viral diseases in Australia. The company has market cap of $9.13 million. The Company’s lead antiviral drug is BIT225, which is in Phase II clinical trials for the treatment of HIV-1 and hepatitis C virus infections. It currently has negative earnings. The firm also has a portfolio of preclinical antiviral programs developing drugs targeting a range of viral diseases, such as dengue, zika, and influenza virus.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.